With these initial safety and efficacy signals, future first line immunotherapy trials should include this cohort of lung cancer patients to better understand the scope of CNS disease control by PD-1 vs. PD-L1 checkpoint inhibitors given the potential different cell distribution of the respective drug targets and their location relative to the blood brain barrier. This evidence concerns the gene CD274 and lung cancer.